تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Ecolab Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $76.7B | |
|---|---|---|
| Revenue (ttm) | 17.4B | |
| Net income (ttm) | 2.1B | |
| EPS (ttm) | $7.35 | |
| Shares out | 280.3M | |
| P/E (trailing) | 39.8x | |
| P/E (forward) | 29.7x | |
| Dividend | $2.92 (1.00%) | |
| Volume | 889,192 | |
| Beta | 0.88 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $12.73B | $14.19B | $15.32B | $15.74B | $16.08B | +6.0% |
| Gross profit | $5.22B | $5.42B | $6.18B | $6.84B | $7.16B | +8.2% |
| Operating income | $1.60B | $1.56B | $1.99B | $2.80B | $2.74B | +14.4% |
| Net income | $1.13B | $1.09B | $1.37B | $2.11B | $2.08B | +16.4% |
| EPS (diluted) | $3.91 | $3.81 | $4.79 | $7.37 | $7.28 | +16.8% |
| EBITDA | $2.47B | $2.55B | $3.03B | $3.85B | $3.46B | +8.8% |
| R&D | $186.0M | $190.0M | $192.0M | $207.0M | $202.0M | +2.1% |
| SG&A | $3.42B | $3.65B | $4.06B | $4.23B | $4.26B | +5.7% |
Recent company headlines from major financial publishers.
Ecolab executes cleanly on its core operational targets: Water Services preserves steady consumable pricing and volume replenishment, operating margins expand toward guided targets, and China debottlenecking supports steady bioprocessing demand. However, even under this successful operating performance, fundamental cash flows yield Fair value of $203.99, indicating that shares at $273.70 reflect an implied return of -25.5%.
Rapid commercial scaling of CoolIT liquid cooling systems across AI data centers multiplies addressable sales opportunities 3x to 5x, while China purification debottlenecking sustains double-digit life sciences growth toward a 30% ROI. Value pricing overcomes raw material inflation rapidly within three months, accelerating operating margin expansion beyond 20% and driving valuation toward the upper fair value boundary of $251.65.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.0% | $219 | $223 | $227 | $232 | $237 |
| 8.5% | $208 | $211 | $215 | $218 | $223 |
| 9.0% | $198 | $201 | $204 | $207 | $211 |
| 9.5% | $190 | $193 | $195 | $198 | $200 |
| 10.0% | $183 | $185 | $187 | $189 | $192 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
